Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Jefferies Global Healthcare Conference 2026 in New York from June 2-4, 2026.
CEO Faraz Ali is scheduled to present on Thursday, June 4, 2026, at 3:10 p.m. ET, with live and archived webcasts available via Tenaya’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – TNYA
In the May 29 session, TNYA gained 8.77%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.9% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Clinical data update | Positive | -8.3% | Positive interim RIDGE-1 TN-401 data with EMA PRIME designation for PKP2 ARVC. |
| May 06 | Earnings and update | Positive | +7.4% | Q1 2026 results with $80.9M cash, Alnylam deal, and 2026 clinical readout plans. |
| Apr 27 | Conference data preview | Positive | +4.1% | Announcement of late-breaking RIDGE-1 TN-401 oral presentation and ASGCT abstracts. |
| Mar 11 | Earnings and update | Positive | +4.0% | Q4/FY 2025 results with $100.5M cash and December offering bolstering balance sheet. |
| Mar 09 | Preclinical data | Positive | +7.8% | Preclinical TN-301 DMD data and Phase 1 safety supporting plans for Phase 2 development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly seen positive price alignment, with one notable selloff on strong clinical data.
Over the past few months, Tenaya has reported multiple clinical and financial milestones. Clinical updates for TN-401 in ARVC and broader program progress for TN-201 and TN-301 drew generally positive reactions, with four of the last five events producing gains of up to 7.84%. The exception was the May 15 positive RIDGE-1 interim data, which saw a -8.31% move, showing occasional selling into good news. Against this backdrop, a routine conference participation announcement fits a pattern of steady communication between key data and earnings events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of its executive team will present and participate in the upcoming Jefferies Global Healthcare Conference taking place from June 2-4, 2026, in New York, New York. Faraz Ali, Tenaya’s Chief Executive Officer, will provide a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET.
The live webcast of the presentation may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
